omniture
Alteogen, Inc

Latest News

Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology

DAEJEON, South Korea, Nov. 10, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today t...

2024-11-11 08:07 1230

Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase®

* Tergase® poised to capture a fair share of the global hyaluronidase market. DAEJEON, South Kore...

2024-07-08 21:00 2014

Altos Biologics Files for Approval of Aflibercept Biosimilar

DAEJEON, South Korea, July 1, 2024 /PRNewswire/ -- Alteogen Inc. (KO...

2024-07-02 08:00 2792

Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile

Alteogen expects Tergase® will replace commercially available animal-derived hyaluronidase products...

2023-09-05 20:00 1293

Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea® Biosimilar in Neovascular Age-related Macular Degeneration

* Altos Biologics, a subsidiary of Alteogen, is actively engaged in Eylea®  Biosimilar (ALT-L9) cl...

2023-02-22 22:00 2275